Want to see TSHA full AI Analyst Report?
TSHA Stock Chart & Stats
$6.43
-$0.08(-4.26%)
At close: 4:00 PM EST
$6.43
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$2.34 - $7.30
Previous CloseN/A
Volume273.02K
Average Volume (3M)3.79M
Market Cap
$1.91B
Enterprise Value$1.43K
Total Cash (Recent Filing)$276.58M
Total Debt (Recent Filing)$17.77M
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding319,861,020
10 Day Avg. Volume3,322,488
30 Day Avg. Volume3,789,276
Financial Highlights & Ratios
PEG Ratio2.91
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.70Price Target Upside97.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$818.18K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment And BLA PathwayDocumented FDA engagement and alignment on a potential 6-month interim-based BLA materially de-risks regulatory pathway. Initiation of BLA-enabling PPQ using commercial processes advances submission readiness and converts program milestones into tangible regulatory progress over the next 6–12 months.
Robust Clinical Efficacy SignalsConsistent, deep functional improvements and high response rates across treated patients indicate durable clinical benefit potential. Strong efficacy and favorable safety in early cohorts underpin a convincing evidence package for regulators, payers and prescribers, supporting long-term commercial viability if replicated in pivotal data.
Solid Balance Sheet And Secured Financing Extends RunwayA sizable cash balance plus a near-term equity raise meaningfully extends runway into mid/late 2028, lowering immediate refinancing risk and allowing completion of PPQ, pivotal dosing and data readouts. This funding runway supports execution of critical development and regulatory milestones over the medium term.
Bears Say
High Cash Burn And Negative Operating Cash FlowSustained large negative operating and free cash flow reflects that operations consume substantial cash each year. This structural burn rate necessitates continued external funding and creates recurring dilution risk, weakening financial flexibility until commercial revenues materialize or partnerships deliver material cash inflows.
Widening Net Losses From Ramped Development And G&AAggressive increases in R&D and G&A nearly doubled quarterly net loss, structurally increasing cash consumption. While spending supports regulatory readiness, the enlarged cost base pushes profitability farther into the future and raises the scale of financing required before commercialization can offset losses.
Manufacturing And Supply-chain Execution RiskPPQ success and manufacturing comparability are pivotal for BLA timing; reliance on a single primary CDMO and deferred redundancy planning create operational concentration risk. Manufacturing setbacks or inspection issues could delay submission, approval and launch, materially impacting long-term commercialization prospects.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $2.34 and its highest was $7.30 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $1.91B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 29 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on May 06, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.023.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 319,861,020 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went up 0.576%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.70 (97.51% Upside)
$12.70 (97.51% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 322.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.11%
12-Months-Change
Fundamentals
Return on Equity
-56.07%
Trailing 12-Months
Asset Growth
117.08%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
TSHA Stock 12 Month Forecast
Average Price Target
$12.70
▲(97.51% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
2.89% Insiders
8.75% Mutual Funds
0.17% Other Institutional Investors
76.27% Public Companies and
Individual Investors